Immutep Global Webcast to Discuss TACTI-002 Data Presented


SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, will hold a global webcast to discuss new data from 1st line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial, including a question-and-answer session with an analyst.

The new data will be presented in an oral presentation at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) on Friday, June 3, 2022 at 1:00 p.m. U.S. Central Daylight Time (CDT); corresponding to Saturday, June 4, 2022 at 4 a.m. AEST and announced to the market.

Webcast Details

Deaten and time: 8:00 a.m. AEST (Sydney) Tuesday, June 7, 2022 /
5:00 p.m. CDT (Chicago) Monday, June 6, 2022
Speakers: Immutep CEO Marc Voigt, CMO/CSO Dr Frederic Triebel and Christian Mueller, Vice President Strategic Development
Register: https://us02web.zoom.us/webinar/register/3616539572927/WN_fAVtcc30SXuBz-kBxfF86g
Questions: Investors are invited to submit their questions in advance via [email protected].

A replay of the webcast will be available after the event on www.immutep.com.

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3-related immunotherapeutics for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is an antigen-presenting cell (APC) activator first in class explored in cancer and infectious diseases. Immutep is also developing a LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, including antibodies for modulating the immune response, are being developed by Immutep’s large pharma partners.

Further information can be found on the company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

American media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

Previous California's Unprecedented Reparations Report Details 150 Years of Anti-Black Damage
Next Anemia and Vitamin Testing Market is Booming Globally with Top Key Players – Abbott Laboratories, bioMérieux, DiaSorin, F. Hoffmann-La Roche, Siemens, DIAsource ImmunoAssays, Gold Standard Diagnostics, Immunodiagnostic Systems Holdings, Ortho Clinical Diagnostics, Qualigen, Quest Diagnostics - ManufactureLink